A second Phase 3 study of 18F-DCFPyL PET/CT Imaging in patients with biochemical recurrence of prostate cancer

Trial Profile

A second Phase 3 study of 18F-DCFPyL PET/CT Imaging in patients with biochemical recurrence of prostate cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 09 May 2018

At a glance

  • Drugs 18F DCFPyL (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 09 May 2018 According to a Progenics Pharmaceuticals media release, company expects to initiate this trial by year end.
    • 19 Mar 2018 New trial record
    • 08 Mar 2018 According to a Progenics Pharmaceuticals media release, company expects to initiate this second Phase 3 study after completion of enrollment in OSPREY study which is expected in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top